The effectiveness removes the final regulatory barrier for selling stockholders to exit their positions. With a prior S-3 already effective and unused, and the company cash-constrained with a going-concern warning, expect aggressive selling pressure. Monitor for a take-down notice or a material drop below Nasdaq's $1.00 bid price, which could trigger a delisting process. Avoid long positions until the overhang clears or a material positive catalyst (e.g., FDA approval, financing) emerges.
Price Chart
Executive Summary
Citius Oncology's S-3 registration (File No. 333-296360) became effective on June 5, 2026, enabling the resale of up to 32,931,482 shares of common stock underlying warrants and pre-funded warrants held by selling stockholders. The effectiveness clears the contractual path for massive potential dilution of ~35.4% of current shares outstanding, with the prior S-3 from January 2026 already effective and unused, compounding the overhang.
Key Facts
- EFFECT notice dated June 5, 2026, for S-3 registration File No. 333-296360
- Registration covers 32,931,482 shares: 21,656,620 common from warrants, 15,229,358 from pre-funded warrants, 2,859,501 from placement agent warrants
- Company receives no proceeds from this resale registration
- Prior S-3 from January 5, 2026 (154d ago) also effective and remains available
- Issuer has $2.6M cash (as of latest filing), going-concern warning, and non-compliance with Nasdaq $1.00 bid price rule
Financial Impact
Registration enables resale of up to 32.9M shares (~35.4% dilution of current shares outstanding) at zero proceeds to the company. Combined with prior effective S-3, total registered resale overhang is substantial.
Risk Factors
- Selling stockholders can immediately begin disposing shares, creating sustained downward price pressure
- Dual effective S-3 filings (Jan 2026 and this one) compound the overhang uncertainty
- Nasdaq non-compliance and going-concern warning heighten delisting and bankruptcy risk
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001912 |
| Document: 9999999995-26-001912-index.html | 9999999995-26-001912 |
| Document: 9999999995-26-001912.txt | 9999999995-26-001912 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $0.6000 | awaiting T+5 | — | $0.5957 (−0.72%) |
Oct 26, 2026 today | Press Release | $0.6072 | awaiting T+5 | — | $0.5957 (−1.89%) |
Oct 23, 2026 3d ago | 8-K | $0.5795 | awaiting T+5 | — | $0.5957 (−2.80%) |
Aug 12, 2026 10w ago | 8-K | $0.8115 $0.7525 | ▼ −7.27% | ▼ −6.83% | $0.5957 (−26.59%) |
Aug 5, 2026 11w ago | 8-K | $0.7850 $0.8115 | ▲ +3.38% | ▲ +3.03% | $0.5957 (−24.11%) |
Jun 8, 2026 20w ago | EFFECT | $0.7999 $0.6802 | ▲ +14.96% | ▲ +17.08% | $0.5957 (+25.53%) |
Jun 1, 2026 21w ago | 8-K | $0.7830 $0.7200 | ▼ −8.05% | ▼ −5.08% | $0.5957 (−23.92%) |
May 29, 2026 21w ago | S-3 | $0.7920 $0.7800 | ▲ +1.52% | ▼ −1.24% | $0.5957 (+24.79%) |
May 15, 2026 23w ago | 8-K | $0.8290 $0.8600 | ▲ +3.74% | ▲ +2.12% | $0.5957 (−28.14%) |
Mar 3, 2026 33w ago | EFFECT | $1.06 $1.01 | ▼ −5.19% | ▼ −4.71% | $0.5957 (−43.80%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers